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Hypophyseal Growth Hormone 
I I . in teract ion w i t h Other Hormones 
M. Saeed-uz-Zafar, M.D., Raymond C. Mellinger, M.D., and 
Lewis B. Morrow, M.D.* 
Growth hormone (GH) synthesis and release is ronlrolled by hypothalamic GH 
releasing factor. Thyroid hormones, androgens and estrogens in physiologic con-
centrations enhance GH secretion but a controlling role for glucagon and vaso-
pressin in GH release is not established. Under stress, ACTH directly facilitates 
GH release while the similar action of the catecholamines is mediated by the 
a-adrenergic receptors. Though physiologic doses of glucorticoids and progestins 
do not affect GH liberation, prolonged administration of medroxyprogesterone 
acetate or of glucocorticoids in high dosage will decrease blood levels or blunt 
Gti responsiveness. GH enhances the release of insulin. A shift in adrenal steroid 
biosynthesis from the glucocorticoid to the androgenic pathway may also be an 
effect of GH administration. Prolonged elevated GH levels decrease .serum 
thyroid binding globulin but increase the turnover of free thyroxine. Decreased 
thyroidal iodine uptake is probably secondary to these changes in thyroxine 
metabolism. In hypothyroidism and severe Cushing's syndrome GH release is 
blunted. In most cases of acromegaly as well as in hyperthyroidism GH is non-
suppressible, while in diabetes its response to stimuli other than hypoglycemia is 
exaggerated. 
In a previous article' we reviewed 
the functions of growth hormone (GH) 
as a stimulant to growth and as a factor 
regulating intermediary metabolism. 
Its secretion is influenced not only by 
physical, neuronal and metabolic ac-
tivity, as previously discussed, but an 
important interplay also exists between 
GH and other hormones. These hor-
monal relationships are the subject of 
the present discussion. 
Growth Hormone Releasing 
Factor (GHRF) 
The synthesis and release of GH is 
under the direct influence of a hypo-
thalamic neurohumor, growth hormone 
releasing factor (GHRF), which is se-
'"Division of Endocrinology, Department of 
Medicine. 
creted in or around the median emi-
nence. It is transmitted through the 
hypothalamic-hypophyseal portal sys-
tem to the anterior pituitary where it 
promotes synthesis and release of GH 
by the eosinophilic cells. 
Low plasma GH levels and poor re-
sponse to hypoglycemia have been ob-
served in children with emotional de-
privation and growth retardation. GH 
response to hypoglycemia became nor-
mal after a few days in a supportive 
environment and normal growth re-
sumed. Powell et al- believe that de-
privation of maternal love in some way 
reduces GH secretion in these children. 
The situation may be analogous to 
anorexia nervosa, in which GH de-
ficiency has also been observed, in 
contrast to starvation in which GH 
levels are reportedly very high. Pre-
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sumably, alterations in GHRF are re-
sponsible for the GH changes charac-
teristic of these clinical states. 
Vasopressin 
Gagliardino et aP demonstrated a 
rise in plasma GH levels after admin-
istration of vasopressin to 15 normal 
men, women and children. The peak 
response occurred 30 minutes after 
intramuscular injection. Previously, 
others had demonstrated a GH stimu-
latory effect of lysine-vasopressin in 
two normal female subjects but not in 
males.* Although vasopressin also stim-
ulates ACTH and TSH release, both 
of which are under hypothalamic con-
trol, it is unlikely that this polypeptide 
plays a physiologic role in anterior 
lobe secretory activity. 
Corticotrophin (ACTH) 
Zahnd et aP recently demonstrated 
that 1 mg of synthetic ACTH stimu-
lated GH release in six normal sub-
jects comparable to that which fol-
lowed insulin-induced hypoglycemia. 
The time of peak response ranged from 
15 to 90 minutes and the earliest, 
highest response occurred in the only 
female subject tested. The authors pro-
pose that ACTH is a possible mediator 
of stress-induced GH release. 
Islet Cell Hormones 
Although insulin and glucagon both 
stimulate GH secretion, the mechan-
isms of their acdon are somewhat dif-
ferent. Well-known are the opposing 
effects of these hormones on the level 
of glucose, the primary regulator of 
GH secretion. Insulin increases glu-
cose utilization and lowers blood sugar, 
stimulating GH secretion. GH, in turn, 
tends to raise blood glucose by inter-
lering with its utilization, by increasing 
glycogenolysis and by accelerating glu-
coneogenesis. 
Consequent to the rise in glucose 
and possibly by direct islet cell stimu-
lation, growth hormone causes syn-
thesis and release of insulin. With pro-
longed administration, persistently ele-
vated blood sugar may result despite 
elevated insulin levels as seen in dia-
betes of acromegaly.'' Even with nor-
mal blood sugar levels, plasma insulin 
in acromegalics has been found three 
times greater than that of controls.'' 
Although increased islet cell stimula-
tion secondary to GH effect on the 
blood sugar may account for the in-
creased insulin secretion, a markedly 
increased insulin secretory capacity 
can also be demonstrated, for example, 
by tolbutamide testing in acromegalic 
patients.'' A similar priming effect on 
the beta cells is indicated by the exag-
gerated insulin response to tolbutamide 
administered to dogs treated with GH.'^ 
This increased secretory reserve corre-
lates with the islet cell hypertrophy 
demonstrated in acromegalic subjects 
by Recant" as well as in various labora-
tory animals treated with growth hor-
mone. 
The extraordinary insulin secretory 
capacity of acromegalic subjects can 
also be demonstrated by challenge with 
a glucocorticoid (eg, dexamethasone 8 
mg/day for 2 days). Under these con-
ditions, normal individuals exhibit a 
four- to fivefold increase in plasma 
insulin response to tolbutamide. Similar 
treatment of acromegalic subjects re-
sults in a tenfold increase in plasma 
insulin levels. 
No significant change in plasma in-
sulin was found by Daughaday and 
Kipnis" in normal subjects 30 minutes 
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after a single intravenous injection of 
5 mg of GH. However, administration 
of 10 mg/day for 3-8 days to hypopi-
tuitary subjects produced a progressive 
increase in both blood sugar and 
insulin. Furthermore, carbohydrate tol-
erance was diminished despite a six-
fold increase in plasma insulin re-
sponse. 
On the other hand, plasma GH in 
diabetics differs from that of normals 
in that diabetics are more sensitive to 
GH releasing stimuli other than hypo-
glycemia. This phenomenon does not 
correlate with the presence or absence 
of retinopathy. 
Recently, Mitchell et aP'^  demon-
strated an elevation of plasma GH in 
15 individuals within three hours of 
the subcutaneous injection of 1 mg of 
glucagon. Most often, the peak eleva-
tion occurred at two hours and changes 
in blood glucose alone could not ex-
plain the rise in GH. This observation 
is contrary to previous reports that glu-
cagon does not stimulate GH release 
but the authors contend that the GH 
levels in earlier studies were not ob-
served beyond 90 minutes. The exact 
mechanism of glucagon-induced stimu-
lation of GH release is not known but 
the late falling glucose levels may con-
tribute or may reflect merely a physi-
ologic fluctuation of GH release. 
Corticosteroids 
Observations concerning the effects 
of glucocorticoids on GH release are 
conflicting. The absence of normal 
spontaneous GH peaks in two patients 
with Cushing's syndrome was demon-
strated by Stiel et a l ," but this phe-
nomenon was not reproduced in nor-
mal subjects treated with prednisone 
15 mg daily. Both Hartog et aP'' and 
Frantz and Rabkin '" reported that in 
adults receiving corticosteroids, GH 
response to hypoglycemia is blunted. 
Morris et aP' failed to confirm this 
claim in children. Our study of growth 
hormone in 12 patients with Cushing's 
syndrome concludes that the suppres-
sion of GH response to hypoglycemia 
which occurs in the hypercortical state 
is proportional to the duration and 
severity of the adrenal hypersecretion. 
In these cases, impaired GH release 
did not depend upon glucose levels, and 
responsiveness was restored with re-
mission of the Cushing's syndrome in 
all except one patient who had de-
veloped a pituitary tumor. In children 
and adolescents with Cushing's syn-
drome, growth had ceased despite 
normal GH response to hypoglycemic 
stimulus."" These observations, consis-
tent with the findings in prepubertal 
children receiving corticosteroid treat-
ment, suggest that the impaired growth 
is the result of steroid-induced anta-
gonism to GH at the tissue level.i* !** 
Strauch et al-*^ ' studied GH releasing 
mechanisms in Cushing's syndrome 
utilizing insulin, glucose and arginine. 
In nine patients who did not respond 
to falling glucose, arginine provoked a 
GH release in all but three, two of 
whom were male. The authors conclude 
that this "partial somatotrophin de-
ficiency" in Cushing's syndrome is due 
to hypothalamic GHRF inhibition and 
that the pituitary GH secretory mech-
anism is intact. A similar mechanism 
may explain the exaggerated GH re-
sponse in diabetics who also respond 
to stimuli other than hypoglycemia. 
We have studied GH response to 
arginine in four patients with the adren-
ogenital syndrome, and have evaluated 
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Table I 
Age o 
Name Sex* 
RC 
DC 
LP 
17M 
13M 
19F 
State 
EFFECT OF GLUCOCORTICOID THERAPY ON GROWTH HORMONE RESPONSE 
TO ARGININE IN ADRENOGENITAL SYNDROME 
Growth Hormone mUg/ml 
0 Min. 30 Min. 45 Min. 60 Min. 75 Min. 90 Min. 120 Min. 
Untreated 12.4 15.4 16.8 6.0 3.8 2.0 13.6 
TRIAMCINOLONE 15.0 50 > 100 80 53 20 14.5 
Untreated 1.4 10.0 18.4 12.0 3.4 1.8 7.6 
TRIAMCINOLONE 6.0 2.0 2.0 2.8 13.2 27.0 21.0 
Untreated 3.0 14.0 54 30 11.6 44.0 
PREDNISONE 13.4 60 74.0 68 54 44 7.8 
P'triol 
150 Min. Mq/24-hr 
12.4 
11.5 
19.8 
9.7 
7.0 
4.8 
32.6 
0.5 
30.0 
1.4 
30.5 
2.3 
TO 
CD 
03 
a. 
o 
CC 17F Untreated 
PREDNISONE 
2.4 24 
6.8 > 100 
> 100 
> 100 
80 
100 
> 100 
> 100 
> 100 
> 100 
26.0 
44.0 
10.4 
9.6 
65.0 
3.3 
RC and DC were given triamcinolone and GH response was tested four weeks later. In cases 
of LP and CC long-term prednisone treatment was discontinued a month before arginine 
stimulation. The higher GH response during treatment is not statistically different from 
untreated values. The very high levels in CC are unexplained. 
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the effect of glucocorticoid therapy. 
Although there was no statistical dif-
ference in GH levels, adrenal suppres-
sion treatment tended to improve the 
GH response (Table I) . In one patient 
(CC) GH levels were very high after 
arginine, and were not affected by cor-
ticoid therapy. The somewhat higher 
GH levels during corticosteroid ad-
ministration were unexpected in view 
of the tendency of Cortisol to reduce 
GH response in other patients. A pos-
sible explanation is suggested by the 
work of Lawrence and others who have 
studied the suppressive effect of med-
roxyprogesterone acetate on GH re-
lease.-' This drug is a methylated de-
rivative of 17-hydroxyprogesterone 
which is secreted in high titer by un-
treated patients with the adrenogenital 
syndromes. Urinary pregnanetriol in-
dicates the 17-hydroxyprogesterone 
secretion in our patients and the sup-
pressive effect of treatment. Conceiv-
ably, this steroid or its metabolites 
account for the somewhat lower GH 
response observed during the untreated 
state. The extraordinary response of 
patient CC (Table I), unique to our 
experience, is unexplained. 
At the present time there is no 
convincing evidence that the cortico-
steroids normally influence GH release. 
Although physiological doses of Corti-
sol enhance GH production in tissue 
cultures of normal human pituitaries as 
well as eosinophilic adenomas,-- there 
is little doubt that pharmacological 
doses of these steroids can impair GH 
release and most assuredly antagonize 
the growth-promoting effects of the 
hormone. 
Another subtle relationship may exist 
between GH and adrenocortical secre-
tions. GH administration is capable 
of altering the adrenal response to cor-
ticotropin. Rats treated with HGH and 
prolactin release less corticosteroid in 
response to ACTH than do control 
animals.-'' Similarly, basal 17-hydroxy-
corticoid secretion is reduced in dogs 
treated with HGH preparations and 
this response is dose-related.-^ In nor-
mal human subjects as well as in pa-
tients with Cushing's syndrome, GH 
reportedly lowers urinary 17-hydroxy-
steroids.--'^  On the other hand, GH 
probably enhances adrenal androgen 
secretion, and hirsuitism is a common 
clinical finding in acromegalic females. 
Reasoning from the characteristic ele-
vation of urinary 17-ketosteroids in 
acromegaly, Lim and Dingman-'' postu-
lated GH-induced activation of adrenal 
androgenic steroidogenesis. An acro-
megalic patient has been reported with 
non-suppressible adrenal function, vi-
rilization, high GH levels, moderately 
elevated urinary 17-ketosteroids but 
normal 17-hydroxysteroids, presum-
ably the result of excess ACTH secre-
tion in the presence of increased GH.'-" 
To evaluate the possible significance 
of this GH-adrenal cortex relationship 
to growth in childhood, we have studied 
adrenal function in eight GH-deficient 
children receiving HGH therapy. In 
eight-month courses of treatment, a 
small reduction in mean 17-hydroxy-
corticosteroids and Cortisol secretion 
rate occurred in these subjects (Table 
II) , while the urinary androgen metabo-
lites, especially androsterone, increased 
(Table III ) . Al l children responded to 
therapy with accelerated growth. 
Catecholamines 
A role for epinephrine in the control 
of growth hormone secretion is also 
unsettled. Blackard and Heidingsfeld-
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Table II 
EFFECT OF EXOGENOUS GROWTH HORMONE ON URINARY 
17-HYDROXYCORTICOSTEROIDS (17-OHCS) and CORTISOL SECRETION 
RATES (CSR) IN 8 DWARF CHILDREN 
Name Sex*^  
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
RK 6M 9.4 4.0 2.4 1.6 
DB 5M 12.8 4.7 2.4 3=0 
BS 9M 10.3 6.6 2.4 2.7 
WR 8M 10.7 6.0 2.0 1.1 
GM 12M 5.8 3.9 3.4 1.4 
TH 13M 5.6 6.9 2.4 2.7 
RKu 15F 4.1 2.6 2.3 1.0 
MR 12M 7.6 12.4 12.8 5.7 
Mean 8.3 5.9 3.8 2.4 
Two mg of human growth hormone three times weekly was administered for eight months. 
CSR fell in six of eight subjects and urinary 17-OHCS decreased in five. The mean values 
of both CSR and urinary 17-OHCS are lower after treatment but wide variation in the 
subjects precludes statistical analysis. 
er-^  studied the effect of catecholamines 
on plasma GH under conditions of con-
trolled glucose concentration. During 
a-adrenergic blockade, insulin-induced 
hypoglycemia produced a lesser eleva-
tion of growth hormone than that pro-
duced without blockade. Conversely, 
GH levels were higher with insulin-
induced hypoglycemia during ^-adre-
nergic blockade, but inhibition of cyclic 
3'5-AMP phosphodiesterase activity 
with administration of theophylline had 
no detectable effect on plasma GH 
response. This study is interpreted to 
indicate a stimulatory effect by a-
adrenergic receptors and an inhibitory 
effect by /3-adrenergic receptors of 
growth hormone secretion, a pattern 
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Table III 
E 
o 
E 
C3 
TO 
Q) 
EFFECT OF GROWTH HORMONE ON URINARY ANDROGENS 
Name ANDROSTERONE in mg/day ETIOCHOLANOLONE in mg/day Total 0^902 17- KS in mg/day 
& 
Sex 
Before After Before After Before After 
Treatment Treatment Treatment Treatment Treatment Treatment 
RK 6M .006 .003 — .010 .006 .013 
DB 5M .015 .019 .007 .013 .022 .032 
BS 9M .023 .035 .022 .023 .055 
WR 8M .060 .038 .030 .010 .100 .051 
GM I2M .112 .167 .130 .119 .242 .304 
TH 13M .830 1.161 .290 .274 1.150 1.435 
RKu 15F .030 .031 .008 .040 .039 
MR 12M .400 .689 1.065 1.375 
Mean .196 .268 .330 .413 
HGH was administered 2 mg thrice weekly for eight months. In contrast to reduced Cortisol 
secretion, androgen metabolites increased in six of the eight subjects after GH therapy. 
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opposite to the sympathetic mechanism 
controlling the release of insulin. Ap-
parently, catecholamines released dur-
ing hypoglycemia inhibit insulin secre-
tion and assist in promoting a rise in 
GH. The observation that neither ad-
renergic blockade nor theophylline al-
tered basal GH levels suggests that the 
sympathetic nervous system plays no 
role in the control of resting GH levels. 
However, Imura et aF" earlier demon-
strated an elevation of GH after pro-
pranolol administration without other 
stimulus. Their study also supported 
the role of sympathetic receptors in the 
control of GH release. 
Thyroid 
Accelerated growth is a well recog-
nized feature of hyperthyroidism in 
childhood-'" while retarded growth is 
seen in juvenile myxedema.'i An effect 
of thyroid hormone on synthesis and 
secretion of GH is suggested by the 
decrease in the number of pituitary 
acidophils found in patients with myxe-
dema-'- and in rats after thyroidec-
t o m y . j n \)oth children and adults 
with primary hypothyroidism GH re-
lease is impaired in response either to 
insulin-induced hypoglycemia or ar-
ginine. Responsiveness returns to 
normal after adequate treatment, but 
before thyroid therapy the impover-
ished GH response to hypoglcemia may 
suggest an erroneous diagnosis of hypo-
pituitarism. The mechanism by which 
thyroid deficiency influences GH syn-
thesis and release may involve GHRF 
secretion or GH synthesis and storage 
by pituitary cells or both. As stated 
previously, adrenergic receptors in-
fluence growth hormone secretion, and 
thyroxine may exert its effect through 
hypothalamic adrenergic receptors.*" 
In studies of hyperthyroid patients, 
deficient GH release in response to 
insulin-induced hypoglycemia was re-
ported by Burgess**^  but others observed 
normal responses.*^ On the other hand, 
GH suppressibility with glucose is im-
paired in hyperthyroidism and normal 
reactivity returns with restoration to 
the euthyroid state. The mechanism of 
this resistance is unknown.*^ 
Limited evidence indicates that GH 
may affect binding and transport of the 
thyroid hormones. In acromegaly, de-
spite a low or normal free thyroxine 
level, an increased thyroxine turnover 
rate occurs which may partly explain 
the hypermetabolism of the disease.-** 
Exogenous administration of GH 
slightly decreases the thyroxine bind-
ing globulin (TBG) after five days of 
administration and low TBG has been 
reported in long-standing acromegaly.*-"^  
Administration of GH in five-day 
courses to normal volunteers also re-
duced thyroxine binding capacity.*-' 
The lower serum thyroxine levels sec-
ondary to reduced plasma binding may 
be mistakenly interpreted as TSH fail-
ure in subjects receiving GH therapy. 
Root et al*» studied the effect of HGH 
therapy on thyroidal iodine uptake and 
serum PBI in 20 children with stunted 
growth from various causes. In nine 
patients a significant change in uptake 
and PBI was observed: in two iodine 
uptake increased and PBI increased in 
two; in six subjects, both PBI and up-
take decreased. The authors interpret 
these data as indicating diminished 
TSH secretion induced by GH admin-
istration. Because exogenous GH has 
been shown to lower TBG levels, the 
data of Root et al do not permit, in our 
opinion, unequivocal interpretation as 
direct inhibition of TSH. Conceivably, 
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reduced TBG with altered equilibrium 
between the free and bound thyroid 
hormones accounts both for the low-
ered PBI and the diminished TSH 
effect evidenced by lower iodine up-
take. The authors reported TSH assays 
only in two patients who were already 
hypothyroid. The markedly elevated 
levels were somewhat reduced after 
five days of GH administration. 
Gonadal Steroids 
Accelerated growth at puberty, a 
universal physiological phenomenon, 
suggests the possibility of augmented 
growth hormone release in the pres-
ence of gonadal steroids. In support of 
this hypothesis, Martin et al*^  demon-
strated increased GH response to hypo-
glycemia in a single patient after pu-
berty compared with the prepubertal 
values, and in a dwarfed, prepubertal 
child they observed enhanced GH re-
lease after five days of testosterone ad-
ministration. Deller and associates** 
studied a 12-year-old dwarfed, sexually 
infantile male who had negligible GH 
response to hypoglycemia. Twenty 
hours after a single 400 mg dose of 
testosterone, GH response rise to a 
similar stimulus was normal and dur-
ing the next ten weeks the patient grew 
5 cm. lUig and Prader*" observed an 
improved GH response to hypogly-
cemia in four patients with anorchia 
and one with delayed puberty after two 
days of androgen administration. The 
response was more pronounced two to 
three months after treatment. Although 
basal plasma GH levels do not rise at 
puberty, the accelerated growth may 
well be secondary in part to enhanced 
stimulated GH levels. 
GH levels during various phases of 
the menstrual cycle are comparable,'" 
but there is evidence for slight increases 
during the preovulatory and premen-
strual phases. Frantz and Rabkin'^  
demonstrated that estrogen administra-
tion increases ambulatory GH levels 
and Spellacy"- demonstrated similar 
effects in patients using the common 
combination type oral contraceptives. 
Furthermore, the greater GH response 
to hypoglycemia which occurs in pa-
tients receiving the sequential type of 
oral contraceptives is considered to be 
due to the estrogen content of the pill.'^ 
On the other hand, Schwartz^ * postu-
lated antagonism between estrogen and 
GH at the cellular level, indicated by 
their opposite effect on urinary calcium 
and hydroxyproline and the serum 
phosphorus. That such an antagonism 
may be of clinical importance is sug-
gested by our experience with a female 
acromegalic patient, age 58, who had 
undergone oophorectomy seven years 
before diagnosis of her pituitary eosin-
ophilic adenoma. The patient has been 
treated with stilbestrol 5 mg daily with 
periodic interruptions for a period of 
three years. She reports regression of 
hand and foot size, shrinking of the 
gums and jaws, requiring new dentures, 
and relief of headache. GH levels were 
somewhat reduced after a month of 
treatment but returned to pretreatment 
values after six months. (Table IV) 
Simon''" demonstrated a blunting of 
GH release after hypoglycemia in four 
of five men who had received medroxy-
progesterone acetate (MPA) 1 gm in-
tramuscular 48 hours previously. Law-
rence reported that this synthetic pro-
gestin administered orally had similar 
effects.-! In 9 of 11 normal volunteers 
and 11 of 12 acromegalics receiving 
oral MPA, GH response to arginine 
was negligible and in 10 acromegalics, 
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Table IV 
GROWTH HORMONE LEVELS IN A FEMALE ACROMEGALIC 
PATIENT RECEIVING STILBESTROL 
Date Condition 
GH (mug/ml) 
F 2-hr. after glucose 
4-14-66 
4- 28-66 
5- 27-66 
7-21-66 
11-30-66 
9-14-67 
Control 
Stilbestrol 
(5 ml/day) 
62 
41 
52 
59 
62 
37 
24 
48 
53 
77 
Although there is a decrease in both the fasting and post-glucose GH levels one month after 
beginning stilbestrol, GH values are the same as control after 17 months of stilbestrol therapy. 
The corresponding blood glucose values were not significantly changed. In all studies 100 gm 
of glucose was ingested after the control specimen was obtained. The patient reported 
objective improvement in her acromegalic features. 
GH levels were strikingly reduced. 
Chronic therapy improved the appear-
ance of two. Malaskey and Daughaday'*^  
recendy recorded the 24-hour profile of 
GH secretion and the response to insu-
lin and arginine infusion in five acro-
megalics with very high GH levels who 
were treated with 40 mgm MPA daily 
for six months. During the first two 
weeks, GH was elevated in four of five 
patients but thereafter levels fell sig-
nificantly and clinical improvement 
occurred. We observed no effect from 
MPA given parentally, 100 mg/week 
to a post-menopausal female acro-
megalic subject. Headache seemed to 
improve after treatment but neither the 
basal nor post-glucose GH values were 
improved and the blood sugar increased 
and hypoglycemic drug therapy was 
required. (Table V) 
Discussion 
The complex functional interrela-
tionships of the hypophyseal polypep-
tide termed "growth hormone" are 
barely implied by this simple designa-
tion. Even after growth and maturation 
are completed the continuing GH secre-
tion helps to regulate the supply and 
utilization of energy substrate while 
protecting the integrity of structural 
proteins. Throughout life, GH facili-
tates the incorporation of ingested pro-
174 
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Table V 
GROWTH HORMONE LEVELS IN AN ACROMEGALIC 
TREATED WITH MEDROXYPROGESTERONE ACETATE (MPA) 
Date Condition GH (mug/ml) 
F 2-hr. 
Blood Glucose (mg. %) 
F 2-hr. 
5- 17-69 
6- 7-69 
Control 
After MPA 
23 
30 
18 
22.5 
90 
95 
155 
230 
MPA (200 mgm) was administered intramuscularly in three doses during the two weeks ending 
May 31, 1969. The two-hour blood sugar is increased after progestin treatment and GH 
values are slightly increased. 
teins and amino acids into body tissues. 
These two broad areas of function, 
mobilization of energy substrate and 
maintenance of tissue, are represented 
by the two prominent GH release 
mechanisms, glucose deficiency and 
amino acid plethora. 
The manifold interactions between 
GH and other hormones may also be 
interpreted in terms of regulating 
growth, preserving body structural in-
tegrity and providing readily accessible 
energy stores. In this regard, enhanced 
GH response to stimulation observed 
in the presence of androgens and estro-
gens may contribute to the accelerated 
growth of adolescence. Moreover, the 
synergistic anabolic activity of GH and 
androgens undoubtedly promotes pu-
bertal growth. The observed peripheral 
antagonism between GH and estrogens 
is less clearly of utility to the body 
economy. It is possible that peripheral 
antagonism between GH and estrogens 
contributes to fat deposition in the sub-
cutaneous tissues of the females. 
The suppressive effect of pharma-
cological doses of synthetic progestins 
on GH release has no known physio-
logical significance. It may help inter-
pret GH levels in our studies of patients 
with congenital adrenal hyperplasia 
who had a marked hypersecretion of 
17-hydroxyprogesterone in the untreat-
ed state. During adrenal suppression by 
corticosteroid administration, GH lev-
els were slightly increased. 
Corticosteroids in high dosage im-
pair GH release especially after pro-
longed administration or hypersecre-
tion. To a less striking degree, admin-
istered GH may in turn diminish 
adrenal Cortisol secretion. A prominent 
antagonism exists between GH and 
corticosteroids in their cellular effects 
and growth of children is markedly 
impaired by excess corticoids even 
without suppressed GH release. The 
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adrenal function studies in our GH-
deficient children receiving physiologic 
doses of HGH also indicated a slight 
reduction of Cortisol secretion, an effect 
which theoretically enhances the 
growth-promoting action of the ad-
ministered hormone. At the same time, 
and very likely as a concomitant of the 
lowered Cortisol secretion, urinary an-
drogen metabolites increased. Adrenal 
androgen secretion normally increases 
progressively and disproportionately in 
the growing child, a phenomenon 
termed "adrenarche," and the andro-
gen undoubtedly promotes the accel-
erating late childhood growth. That 
GH contributes to the adrenarche 
through its influence on adrenocortical 
secretion of corticoids and androgens 
seems a permissible speculation. 
Insulin-deficient children do not 
grow normally even in the presence of 
GH and augmented insulin secretion is 
a predictable result of GH administra-
tion to normal subjects. Thus, GH and 
insulin are mutually stimulatory al-
though the relationship depends on 
their opposing effect on plasma glu-
cose, apparently the ultimate regulator 
of the secretion of both hormones. 
Whereas GH and insulin respond in 
opposite ways to glucose levels, amino-
acidemia is stimulatory to the release 
of both polypeptides, presumably 
through a mechanism not involving 
glucose. 
Growth failure in hypothyroidism is 
in part due to GH failure. Similar 
impaired secretion has not been demon-
strated for the other pituitary hormones 
in myxedema, and TSH is predictably 
elevated. Thyroid hormone corrects the 
impaired GH release. GH administra-
tion modifies plasma binding of the 
thyroid hormone and a fall in PBI may 
not necessarily reflect a decrease in 
TSH secretion. Impaired thyroid secre-
tion as a result of GH action, if proved 
to be a physiologic fact, has no obvious 
biologic utility since thyroid hormone 
is required for optimal growth. 
There is litde evidence that inter-
action between GH and ACTH, vaso-
pressin, the catecholamines, the gluco-
corticoids and glucagon are significant 
in everyday life. However, in condi-
tions of physiologic stress in which 
ACTH and the catecholamines are 
liberated, subsequent release of GH 
provides a reparative, anabolic or anti-
catabolic function. The reported GH 
stimulatory effects of ACTH and of 
the a-receptors of the sympathetic 
nervous system offer a mechanism for 
this reaction. Inasmuch as augmented 
GH levels are not sustained in stress 
states, the protective function of the 
hormone has limited significance. 
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